Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NanoViricides, Inc.
Appointments: BMS CCO Leaves, New Medical Heads At Astellas Americas, Epizyme, CEOs At NanoViricides, Aeglea, Waverley Pharma
Bristol-Myers Squibb's CCO Murdo Gordon has exited the company in the week of its Q2 results, while Trevi Therapeutics, Turnstone Biologics, Aeglea BioTherapeutics, Acadia Pharmaceuticals, NanoViricides and Waverley Pharmaceuticals add to their C-suite. Medical heads join Epizyme and Astellas Americas.
The renewed break-out of a frighteningly deadly virus with no known cure or vaccine in a region that will shortly host a couple of million international pilgrims has prompted a rash of recent headlines linking Middle East Respiratory Syndrome (MERS), the SARS-like coronavirus that first emerged in Saudi Arabia in 2012, and the annual Hajj to Mecca.
AbbVie became the latest firm to test the FDA "voucher" strategy as a pathway to success – entering into a $350m deal with United Therapeutics in an effort to get an experimental medicine to the market quicker.
The unprecedented scale of the Ebola epidemic in West Africa has prompted a similarly unprecedented interest in the response from the pharma and biotech industries to develop treatments and vaccines against the virus.